Bruce Arthur, MD
Critical Care Medicine · Fishers, INNPI 1205956018
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 235 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $795 and has fallen 78.5% since, to $171 in 2025.
Across 235 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$621
- AstraZeneca$510
- Grifols USA, LLC$358
- Inspire Medical Systems, Inc.$269
- Boehringer Ingelheim$222
- Sanofi$199
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,85097%
- Education$1323%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 46 | $621 |
| AstraZeneca(2 entities) | 31 | $510 |
| Grifols USA, LLC | 37 | $358 |
| Inspire Medical Systems, Inc. | 2 | $269 |
| Boehringer Ingelheim | 14 | $222 |
| Sanofi | 10 | $199 |
| Actelion Pharmaceuticals US, Inc. | 9 | $169 |
| Teva Pharmaceuticals USA, Inc. | 6 | $141 |
| Integra Lifesciences Corporation | 1 | $121 |
| Sanofi-aventis U.S. LLC | 2 | $119 |
| Pfizer | 8 | $115 |
| Genentech USA, Inc. | 6 | $114 |
| Johnson & Johnson | 7 | $110 |
| Philips North America LLC | 6 | $110 |
| Insmed, Inc. | 6 | $107 |
| Regeneron Healthcare Solutions, Inc. | 4 | $103 |
| Merck | 5 | $88 |
| Sunovion Pharmaceuticals Inc. | 7 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $64 |
| Mylan Specialty L.p. | 4 | $63 |
| United Therapeutics Corporation | 2 | $48 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Shionogi Inc | 1 | $32 |
| Electromed, Inc. | 3 | $30 |
| Novartis | 2 | $25 |
| Mallinckrodt Hospital Products Inc. | 2 | $25 |
| Baxter Healthcare | 1 | $19 |
| Siemens Medical Solutions USA, Inc. | 1 | $16 |
| EKOS Corporation | 1 | $15 |
| Vapotherm Inc | 1 | $14 |
| Resmed Corp | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,982 in reported general payments places this provider in the 85th percentile of 158 critical care medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 15 | $211,872 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $41,417 |
| Spiriva RespimatTiotropium Bromide | 28 | $20,326 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $13,468 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $11,772 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $10,212 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $9,983 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $914 |
| Fluticasone Propionate | 26 | $546 |
| Montelukast Sodium | 26 | $229 |
| Prednisone | 18 | $117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $222 | $243,96961 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $621 | $51,62983 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $510 | $23,45247 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 158 critical care medicine providers in Indiana.
Other critical care medicine in Fishers
- Vrushank PatelIndianapolis$142K
- Matthew KoscielskiSouth Bend$118K
- Christopher KnieseIndianapolis$44K
- Stanley NasrawayIndianapolis$34K
- Ismail Al-AniSouth Bend$25K
- Horia DraghiciuRichmond$21K
- Shashikumar GowdaTerre Haute$20K
- Laura RodriguezMerrillville$15K
- Ryan BoenteIndianapolis$15K
- Derrick FergusonBloomington$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.